EP1490039A2 - Unite de liaison de systemes therapeutiques transdermiques separables individuellement - Google Patents

Unite de liaison de systemes therapeutiques transdermiques separables individuellement

Info

Publication number
EP1490039A2
EP1490039A2 EP03744842A EP03744842A EP1490039A2 EP 1490039 A2 EP1490039 A2 EP 1490039A2 EP 03744842 A EP03744842 A EP 03744842A EP 03744842 A EP03744842 A EP 03744842A EP 1490039 A2 EP1490039 A2 EP 1490039A2
Authority
EP
European Patent Office
Prior art keywords
drug
unit according
transdermal
base film
therapeutic systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03744842A
Other languages
German (de)
English (en)
Inventor
Klaus M. Wilsmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of EP1490039A2 publication Critical patent/EP1490039A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs

Definitions

  • the invention relates to a coherent unit of isolable, transdermal, therapeutic systems.
  • Transdermal, therapeutic systems for the application of transdermally administered drugs are known. These are technically specified plaster systems that continuously release a therapeutic agent via the skin to a human or animal organism over a certain period of time.
  • the active ingredient may be dispersed in a matrix or present in a drug reservoir. Both in the matrix and in the drug reservoir, it is possible to use the drug liquid, semi-solid or solid or as a corresponding drug formulation.
  • the known transdermal therapeutic systems contain a certain predetermined dose of controlled release drug.
  • the problem here is the individual dosage of the drug according to the patient requirements.
  • a strip-shaped, transdermal, therapeutic system is recommended for this purpose, from which a piece can be separated according to the patient's requirements.
  • the separation takes place in the active substance-containing area.
  • active ingredient can be lost in part and small separation inaccuracies already lead to a different dosage of the active ingredient. An exact dosage is therefore not possible.
  • the active ingredient-containing area can be partially covered in order to achieve a lower dosage. This will, however, if necessary a part of the active ingredient was not used. Furthermore, the skin contact of the active substance-containing area may be impaired.
  • This object is achieved according to the invention by providing a coherent unit comprising at least two isolable, transdermal, therapeutic systems comprising each
  • an active substance-impermeable base film b) an adhesive, the base film at least partially covering and either a drug reservoir or drug-containing matrix having layer having an active substance-free, peripheral edge region and optionally c) a the adhesive layer at least partially covering, peelable protective film,
  • singular, transdermal, therapeutic systems have in their contiguous drug-free border areas separation possibilities.
  • the separation options are each preferably arranged so that they allow a separation of each coherent, transdermal, therapeutic system completely from the unit according to the invention.
  • Suitable active ingredients are all transdermally administrable active substances, such as corticosteroids, analgesics, sedatives, tranquilizers, antibiotics, anesthetics, antiviral agents, antimicrobials, fungicides, vitamins, antiepileptics, sex hormones, nicotine, psychotropic drugs, coronary dilators, antiarthritics, antiasthmatics, antidepressants, antidiabetics, Antihistamines, anti-inflammatories and / or antimigraine agents.
  • active substances such as corticosteroids, analgesics, sedatives, tranquilizers, antibiotics, anesthetics, antiviral agents, antimicrobials, fungicides, vitamins, antiepileptics, sex hormones, nicotine, psychotropic drugs, coronary dilators, antiarthritics, antiasthmatics, antidepressants, antidiabetics, Antihistamines, anti-inflammatories and /
  • the unit according to the invention or an isolated system for controlling pain is suitable.
  • the individualizable, transdermal systems comprise a base film and thereon an adhesive, with a drug-containing matrix or a drug reservoir layer provided, which may optionally have a protective film.
  • the adhesive layer may consist, at least in some areas, preferably completely, of matrix material which contains an adhesive component, preferably a pressure-sensitive adhesive component, and comprises an active substance-containing region. This active substance-containing area is surrounded by a peripheral, drug-free edge area.
  • the drug-impermeable base film is preferably made of a flexible, stretchable, breathable, durable material. Particularly preferred is a textile-like fabric.
  • the base film may be colored, preferably skin-colored.
  • Substance-impermeable means that the base film, at least in the region in which a drug-containing matrix is present, the base film is drug-impermeable. If the base film itself is not impermeable to active substance, an active substance-impermeable barrier layer should be applied between the matrix layer or the active substance reservoir and the base film. This barrier layer should preferably consist of a film-forming polymer.
  • the matrix material of layer b.) May be based on lipophilic or hydrophilic polymers.
  • Hydrophilic polymer matrices may be hydrous, which are preferably gels.
  • Suitable matrix materials are crosslinkable polymers, preferably synthetic resins, silicone rubber or rubber, such as styrene-isoprene-styrene block copolymers, silicones, polyacrylates, polyurethanes, polyvinyl ethers, polyvinyl chloride, polyvinyl alcohols, polyvinylpyrrolidones, polyesters, polypropylene and / or polysaccharides , Particularly preferred are polyacrylates.
  • a skin-compatible polymeric adhesive is used, more preferably a pressure-sensitive adhesive such as hot melt.
  • the adhesive component can be mixed with the matrix materials listed above in known amounts and an active ingredient can be added to produce the active ingredient-containing matrix region.
  • the active ingredient-containing matrix region is applied to the base film in such a way that a drug-free, peripheral edge region is provided.
  • the matrix material can also be crosslinked if necessary.
  • the active substance present in the matrix or the active substances present in the matrix can be liquid, semisolid or solid in the dispersed state or can be incorporated as an appropriate formulation with the addition of customary excipients as active ingredient formulation.
  • adjuvants compounds which enhance or facilitate the transdermal transport of the active ingredients can be used. These adjuvants can mixed with the active ingredients or present in a separate layer to the active ingredient-containing matrix layer.
  • the active substances to be transdermally applied are present in a drug reservoir in the adhesive layer, this reservoir is preferably embedded in the adhesive layer.
  • Suitable adhesives for this layer are the abovementioned polymeric adhesives which are listed as an adhesive component.
  • the active substance reservoir preferably contains the active substance or the corresponding active substance formulation as a solution which can diffuse unhindered through the membrane of the active substance reservoir.
  • Suitable membrane materials are the polymers listed above, which can also be used as matrix material.
  • the transdermal system can also be designed so that only in the edge zone, which is drug-free, the adhesive component is present as a matrix component.
  • the transdermal therapeutic system according to the invention has, at least in the drug-releasing region, preferably over the entire adhesive layer, a protective film which is easily removable before application.
  • this protective film is made of paper or is a slightly adherent physiologically harmless plastic film.
  • the coherent, transdermal therapeutic system according to the invention preferably contains the same dose of active ingredient per system, whereby the individual, demand-dependent application for the patient or user is considerably facilitated. This is especially true when fluctuations in drug demand occur, for. B. in recurrent attacks of pain or when a decaying therapy with decreasing Dosage is necessary.
  • inventive, transdermal, therapeutic systems can first be treated as needed and be made by reducing the number of systems in the course of therapy, the necessary reduction of the drug dose in a simple manner by the patient.
  • the contiguous unit of isolable, transdermal, therapeutic systems according to the invention is preferably present in a packaged form, wherein sterile packaging is also possible if required.
  • FIG. 1 shows a plan view of a unit (1) according to the invention from 4 isolatable, transdermal, therapeutic systems.
  • FIG. 2 shows a plan view of a unit (1) according to the invention from 2 isolatable, transdermal, therapeutic systems.
  • Each isolatable system comprises an active substance-containing matrix region (3) or an active substance-containing reservoir (3a) which is surrounded by an active agent-free, adhesive-capable, peripheral edge region (2).
  • the base film and an optionally present protective film are not shown separately in FIGS. 1 and 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une unité de liaison réunissant des systèmes thérapeutiques transdermiques séparables individuellement.
EP03744842A 2002-03-27 2003-03-22 Unite de liaison de systemes therapeutiques transdermiques separables individuellement Withdrawn EP1490039A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10213772A DE10213772A1 (de) 2002-03-27 2002-03-27 Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
DE10213772 2002-03-27
PCT/EP2003/003004 WO2003079962A2 (fr) 2002-03-27 2003-03-22 Unite de liaison de systemes therapeutiques transdermiques separables individuellement

Publications (1)

Publication Number Publication Date
EP1490039A2 true EP1490039A2 (fr) 2004-12-29

Family

ID=27816006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03744842A Withdrawn EP1490039A2 (fr) 2002-03-27 2003-03-22 Unite de liaison de systemes therapeutiques transdermiques separables individuellement

Country Status (9)

Country Link
EP (1) EP1490039A2 (fr)
JP (1) JP2005520844A (fr)
AR (1) AR039137A1 (fr)
AU (1) AU2003226695B2 (fr)
CA (1) CA2480683A1 (fr)
DE (1) DE10213772A1 (fr)
PE (1) PE20031015A1 (fr)
PL (1) PL370886A1 (fr)
WO (1) WO2003079962A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400685D0 (sv) * 2004-03-19 2004-03-19 Pfizer Health Ab Means for transdermal administration of nicotine
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
JP4782438B2 (ja) * 2005-02-17 2011-09-28 日東電工株式会社 貼付製剤
DE202005014347U1 (de) 2005-09-09 2007-01-18 Grünenthal GmbH Applikationssystem für ein wirkstoffhaltiges Pflaster und Wirkstoffabgaberegulierungsmittel
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
ES2443966T3 (es) * 2010-06-10 2014-02-21 Medskin Solutions Dr. Suwelack Ag Biomatrices perforadas estratificadas
EP2618822B1 (fr) 2010-09-23 2020-02-26 Aquestive Therapeutics, Inc. Procédé et système de formation d'un produit pharmaceutique directement sur une surface d'emballage
AR089201A1 (es) 2011-12-12 2014-08-06 Lohmann Therapie Syst Lts Sistema de suministro transdermico
PT2810646T (pt) 2013-06-04 2016-10-05 Lts Lohmann Therapie Systeme Ag Sistema de administração transdérmica
WO2017201190A1 (fr) 2016-05-18 2017-11-23 Shanghai Yanfeng Jinqiao Automotive Trim Systems Co. Ltd Ensemble console pour intérieur de véhicule
US11572723B2 (en) 2019-02-27 2023-02-07 Shanghai Yanfeng Jinqiao Automotive Triim Systems Co. Ltd. Vehicle interior component
CN111359441B (zh) * 2020-03-25 2022-02-15 青岛科技大学 一种碱性pH响应聚合物纳米容器填充耐氯反渗透膜的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2449865B2 (de) * 1974-10-17 1981-06-19 Schering Ag Berlin Und Bergkamen, 1000 Berlin Folienförmiges Arzneimittel
EP0252459A1 (fr) * 1986-07-07 1988-01-13 Schering Corporation Système d'apport compartimenté agissant à travers la peau
DE3630603A1 (de) * 1986-09-09 1988-03-10 Desitin Arzneimittel Gmbh Darreichungs- und dosierungsform fuer arzneimittelwirkstoffe, reagentien oder dergleichen sowie verfahren zu deren herstellung
KR970008118B1 (ko) * 1987-07-09 1997-05-21 엘테에스 로오만 테라피-지스테메 게엠베하 운트 콤파니 카게 피부 침투성 치료 시스템
DE3911617A1 (de) * 1988-10-12 1990-04-19 Klaus Brueckner Darreichungsform fuer arzneistoffe
CA2090598A1 (fr) * 1992-03-04 1993-09-05 Kirti Himatlal Valia Patch titrable transdermique et methode d'administration de substances therapeutiques
DE4223004A1 (de) * 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
US5242433A (en) * 1992-12-07 1993-09-07 Creative Products Resource Associates, Ltd. Packaging system with in-tandem applicator pads for topical drug delivery
DE19503336C2 (de) * 1995-02-02 1998-07-30 Lohmann Therapie Syst Lts Arzneiform zur Abgabe von Wirkstoffen an Wunden, Verfahren zu ihrer Herstellung und ihre Verwendung
DE29511878U1 (de) * 1995-07-22 1996-11-28 Labtec Gesellschaft für technologische Forschung und Entwicklung mbH, 40764 Langenfeld Transdermale Therapeutische Systeme
DE19900645C2 (de) * 1999-01-11 2003-03-20 Deotexis Inc Transdermales therapeutisches System
US6221384B1 (en) * 1999-11-05 2001-04-24 Anthony C. Pagedas Segmented transdermal dosage unit
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03079962A2 *

Also Published As

Publication number Publication date
WO2003079962A2 (fr) 2003-10-02
WO2003079962A3 (fr) 2003-12-24
AU2003226695A1 (en) 2003-10-08
PL370886A1 (en) 2005-05-30
PE20031015A1 (es) 2004-01-17
CA2480683A1 (fr) 2003-10-02
AU2003226695B2 (en) 2008-10-02
JP2005520844A (ja) 2005-07-14
DE10213772A1 (de) 2003-10-09
AR039137A1 (es) 2005-02-09

Similar Documents

Publication Publication Date Title
DE3714140C2 (fr)
EP0298297B1 (fr) Système thérapeutique transdermique
DE3614843C2 (fr)
DE69401945T2 (de) Einarbeitung eines poly-n-vinylamids in ein transdermales system
DE3634016C2 (fr)
DE69020458T2 (de) Transdermale in zwei Phasen wirkende Ausgabevorrichtung für Medikamente.
DE102006040642A1 (de) Mikronadeln zur Platzierung in der Haut zwecks transdermaler Applikation von Pharmazeutika
EP1450773B1 (fr) Systeme therapeutique transdermique a confort de port longue duree ameliore
DE3905050A1 (de) Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii)
EP1490039A2 (fr) Unite de liaison de systemes therapeutiques transdermiques separables individuellement
DE3908431C2 (fr)
DE3811564C2 (de) Pflaster für Arzneiformulierungen
US20050118245A1 (en) Assembled unit consisting of individually separable, transdermal, therapeutic systems
EP0659079B1 (fr) Systeme therapeutique percutane contenant du pentylenetetrazol comme principe actif
DE69715878T2 (de) Formulierung zur behandlung und/oder vorbeugung von dementia
DE102004045599A1 (de) System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE10025890A1 (de) Dosierung von transdermalen Arzneimittelsystemen
DE102021128912A1 (de) Okklusives pflaster mit flexibler backing
EP1107742A1 (fr) Pansement compose de trois couches et contenant un medicament
DE10025328A1 (de) Acetylsalicylsäure enthaltendes superfizielles therapeutisches System zur Behandlung von Hautschmerzen
DE102006011340A1 (de) Wirkstoffhaltige Pflaster mit verbesserter Handhabung
DE202011004628U1 (de) Atmungsaktives feuchtigkeitstransportierendes transdermales Therapiesystem

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041027

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20060807

17Q First examination report despatched

Effective date: 20060807

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20091008